Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Organon

5 Stocks to Buy for a Harris Presidency

The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.

Kiplinger

If companies don't train Gen Zers, they'll train themselves

Gen Z is having a hard time getting entry-level jobs, plus companies are hiring fewer interns.

Fortune

Organon Stock Sees Relative Strength Rating Rise To 91

A Relative Strength Rating upgrade for Organon shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold

Organon shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 83.

Investors Business Daily

3 Cheap Small-Cap Stocks to Scoop Up on the Market Pullback

With small-cap stocks grabbing investors' attention lately, here are three discounted names with solid fundamentals to grab now, while the retracement provides a prime entry point.

Barchart

3 Healthcare Stocks With The Highest Yields As of June 2024

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

Barchart

Warning over asthma drug after 500 neuropsychiatric reactions reported in young children

UK medicines regulator says information accompanying montelukast will alert users to risk of mood and behaviour changes

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Safety fears over asthma drug after young children suffer severe side effects

Campaigners call for more warnings on montelukast, after reports of night terrors, depression and other mental health events

The Guardian - UK

Drug Maker Organon Stock Scores Relative Strength Upgrade

A Relative Strength Rating upgrade for Organon shows improving technical performance. Will it continue?

Investors Business Daily

9 S&P 500 Stocks Are Screaming Buys According To The 'Fed Model'

Why deal with the S&P 500 when savings accounts pay 5%? That's exactly why many rich people are dumping stocks for cash.

Investors Business Daily

Want long-term contraception? There are more effective options than the pill. But they can be hard to find

Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are. A recent parliamentary inquiry recommends ways to end this “postcode lottery” for people who want to use long-acting reversible contraception.

The Conversation

Organon Stock Scores Market Leadership With Jump To 83 RS Rating

Organon sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

12 Stocks Turned $10,000 To $277,126 In 12 Months

Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.

Investors Business Daily

A simple device could prevent thousands of maternal deaths. Why did it take so long to get to market?

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Bangkok Post

Organon prioritises cross-sectoral collaboration to drive 'Smart Families' progress

Unintended pregnancy remains a significant global health issue. A recent UNFPA report suggesting nearly half of all pregnancies, totaling 121 million each year worldwide, are unintended and more than 160 million women have limited access to contraceptives.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

Upgrades

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up

Organon easily beat first-quarter expectations Thursday despite a dive for its flagship product, Nexplanon, and OGN stock popped.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

Investors Business Daily

Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run

Biotech stock Amphastar hit a record high Friday after U.S. officials approved its generic version of an Organon infertility drug.

Benzinga

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Organon & Co (NYSE: OGN)

Liverpool Echo

Woman covered in burning red rash after taking contraceptive pill

Ella Holley thought the painful red rash was caused by her unhealthy lifestyle of alcohol and late nights

Daily Mirror

Student who thought spotty rash was from partying is told it's a side effect of the pill

Ella Holley initially thought the angry red blotches had been caused by the unhealthy student lifestyle, but is now trying to raise awareness around the potential side effects of taking the contraceptive pill

Investors Business Daily

Organon Pares Early Losses, Climbing On Massive Nexplanon Demand

Organon offered a light 2022 sales outlook on Thursday, but OGN stock recovered from an early dip following the company's beat.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Kennedy News and Media

SP Global Market Intelligence

567 stories

Express

445 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.